Prostate Specific Antigen News and Research

RSS

New prostate cancer test could bring an end to unnecessary biopsies

Researchers have developed a new urine test to diagnose aggressive forms of prostate cancer, which could mean an end to the unnecessary treatment of men with non-aggressive cancers.

26 Jun 2019

A 'health number' that could tell about prostate disease

When it comes to staying on top of your health, doctors often tell you how important it is to "know your numbers." Blood pressure, cholesterol and body mass index can tell you a lot about your heart health, but if you're a man, you need to know one more - your PSA, or prostate-specific antigen.

18 Jun 2019

UCLA physicians find more effective method for detecting prostate cancer

Each year, 1 million men in the U.S. undergo biopsies to determine whether they have prostate cancer. The biopsy procedure traditionally has been guided by ultrasound imaging, but this method cannot clearly display the location of tumors in the prostate gland.

12 Jun 2019

Biomarker correlates with prostate cancer aggressiveness and predicts metastasis to bone

Mortality due to prostate cancer is usually related to its likelihood to metastasize, especially to bone. Prognostic biomarkers are urgently needed to predict disease aggression so that appropriate treatment can be selected.

12 Jun 2019

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.

3 Jun 2019

Only few prostate cancer patients choosing active surveillance follow monitoring guidelines

Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose active surveillance instead of treatment followed the recommended monitoring guidelines.

3 Jun 2019

Prostate cancer marker activates growth factors that contribute to tumor spread

A new study indicates that PSA, a prostate cancer marker, is one of the catalysts that activate vascular endothelial and lymphangiogenic growth factors which contribute to the spread of cancer.

25 May 2019

Black patients less likely to adopt active surveillance for low-risk prostate cancer than white men

At a time when a growing number of men with prostate cancer considered "low risk" are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.

23 May 2019

Single high dose of radiation targeted directly to tumor is safe and effective for prostate cancer

A single high dose of radiation that can be delivered directly to the tumor within a few minutes is a safe and effective technique for treating men with low risk prostate cancer, according to a study presented at the ESTRO 38 conference.

29 Apr 2019

FDA approves new oral treatment for men with certain forms of hypogonadism

The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism.

27 Mar 2019

Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients

In the largest such study so far undertaken, US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients.

18 Mar 2019

New risk model can predict survival of non-metastatic prostate cancer patients

A new risk model, easily accessible on a web interface, can predict the survival of non-metastatic prostate cancer patients, as well as the effect of different treatment approaches on survival.

13 Mar 2019

Community hospitals link arms with prestigious facilities to raise their profiles

After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn’t determine where the residual cancer was lurking.

29 Jan 2019

Interval of time to biochemical failure could be used as surrogate endpoint for prostate cancer

An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure, or the time it takes for previously treated cancer to return as indicated by prostate specific antigen rise, could be used as a surrogate endpoint for locally advanced prostate cancer.

21 Dec 2018

Black men diagnosed with low-grade prostate cancer have higher risk of death, study shows

Black men diagnosed with prostate cancer classified as low risk may actually have a more-aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.

18 Dec 2018

Surgical treatment unnecessary for many prostate cancer patients

Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian men with prostate cancer for 29 years. The results are now published in The New England Journal of Medicine.

12 Dec 2018

Prostate Specific Antigen News and Research

New prostate cancer test could bring an end to unnecessary biopsies

A 'health number' that could tell about prostate disease

UCLA physicians find more effective method for detecting prostate cancer

Biomarker correlates with prostate cancer aggressiveness and predicts metastasis to bone

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Only few prostate cancer patients choosing active surveillance follow monitoring guidelines

Prostate cancer marker activates growth factors that contribute to tumor spread

Black patients less likely to adopt active surveillance for low-risk prostate cancer than white men

Single high dose of radiation targeted directly to tumor is safe and effective for prostate cancer

FDA approves new oral treatment for men with certain forms of hypogonadism

Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients

New risk model can predict survival of non-metastatic prostate cancer patients

Community hospitals link arms with prestigious facilities to raise their profiles

Interval of time to biochemical failure could be used as surrogate endpoint for prostate cancer

Black men diagnosed with low-grade prostate cancer have higher risk of death, study shows

Surgical treatment unnecessary for many prostate cancer patients

Men with inflammatory bowel disease have higher prostate cancer risk

New study confirms effectiveness of PSA screening in reducing prostate cancer deaths

Research aims to address health disparities in African-American men

Baseline PSA levels measured at midlife predict risk of aggressive prostate cancer in black men

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News